# Autifony Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/autifony-therapeutics

- Industry: Biotechnology
- Headquarters: UK
- Website: www.autifony.com
- Total disclosed funding: $13M
- Latest round: Series A (Jun 16, 2015)
- Investors on record: 5

## About

Based in Hertfordshire, UK, and founded in 2011 by CEO Charles H. Large, and CRO Charles H. Large, Autifony Therapeutics Ltd., a.k.a. Autifony Therapeutics is a clinical-stage biotechnology company that focuses on developing medicines to address rare genetic CNS disorders through its ion channel drug discovery platform. In March 2017, Autifony Therapeutics Ltd. raised GBP 1.3 million in funding from Innovate UK and the Dementia Discovery Fund.

The company's primary product pipeline consists of clinical-stage, small-molecule modulators targeting the Kv3 family of potassium channels. These modulators are expected to demonstrate efficacy in treating Fragile X syndrome and rare myoclonic epilepsy syndromes. Additionally, Autifony has preclinical programs utilizing novel Kv3 modulators with potential applications in various CNS disorders, such as schizophrenia and hearing loss.

## Funding rounds

- Series A, Jun 16, 2015, $13M — SV Health Investors, Pfizer Venture Investments, Touchstone Innovations, International Biotechnology Trust, UCL Business plc

## Investors

- SV Health Investors (https://capitalatlas.ai/funds/sv-health-investors) — Series A
- Pfizer Venture Investments (https://capitalatlas.ai/funds/pfizer-venture-investments) — Series A
- Touchstone Innovations (https://capitalatlas.ai/funds/touchstone-innovations) — Series A
- International Biotechnology Trust — Series A
- UCL Business plc — Series A